Immunome Operating Cycle from 2010 to 2026
| IMNM Stock | USD 24.75 0.95 3.70% |
Operating Cycle | First Reported 2010-12-31 | Previous Quarter 6.77 | Current Value 6.02 | Quarterly Volatility 0.39800086 |
Check Immunome financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Immunome's main balance sheet or income statement drivers, such as Net Interest Income of 15.5 M, Interest Income of 15.5 M or Depreciation And Amortization of 2.5 M, as well as many indicators such as Price To Sales Ratio of 33.61, Dividend Yield of 0.0 or PTB Ratio of 3.25. Immunome financial statements analysis is a perfect complement when working with Immunome Valuation or Volatility modules.
Immunome | Operating Cycle | Build AI portfolio with Immunome Stock |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ProphetCheck out the analysis of Immunome Correlation against competitors. To learn how to invest in Immunome Stock, please use our How to Invest in Immunome guide.You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.
Will Biotechnology sector continue expanding? Could Immunome diversify its offerings? Factors like these will boost the valuation of Immunome. Market participants price Immunome higher when confident in its future expansion prospects. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Immunome data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (2.96) | Revenue Per Share | Quarterly Revenue Growth 0.698 | Return On Assets | Return On Equity |
Understanding Immunome requires distinguishing between market price and book value, where the latter reflects Immunome's accounting equity. The concept of intrinsic value—what Immunome's is actually worth based on fundamentals—guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Immunome's price substantially above or below its fundamental value.
Please note, there is a significant difference between Immunome's value and its price as these two are different measures arrived at by different means. Investors typically determine if Immunome is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Immunome's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.